ATE489948T1 - Behandlung von autoimmunkrankheiten - Google Patents

Behandlung von autoimmunkrankheiten

Info

Publication number
ATE489948T1
ATE489948T1 AT06793341T AT06793341T ATE489948T1 AT E489948 T1 ATE489948 T1 AT E489948T1 AT 06793341 T AT06793341 T AT 06793341T AT 06793341 T AT06793341 T AT 06793341T AT E489948 T1 ATE489948 T1 AT E489948T1
Authority
AT
Austria
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
invention describes
Prior art date
Application number
AT06793341T
Other languages
English (en)
Inventor
Rainer Albert
Nigel Graham Cooke
Barbara Nuesslein-Hildesheim
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE489948T1 publication Critical patent/ATE489948T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06793341T 2005-09-09 2006-09-07 Behandlung von autoimmunkrankheiten ATE489948T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
PCT/EP2006/066150 WO2007028821A2 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
ATE489948T1 true ATE489948T1 (de) 2010-12-15

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06793341T ATE489948T1 (de) 2005-09-09 2006-09-07 Behandlung von autoimmunkrankheiten

Country Status (28)

Country Link
US (1) US20080200438A1 (de)
EP (2) EP1926483B1 (de)
JP (4) JP5244598B2 (de)
KR (3) KR101476591B1 (de)
CN (1) CN101257899B (de)
AT (1) ATE489948T1 (de)
AU (2) AU2006289100B2 (de)
BR (1) BRPI0615906A2 (de)
CA (2) CA2820510A1 (de)
CY (1) CY1111285T1 (de)
DE (1) DE602006018629D1 (de)
DK (2) DK1926483T3 (de)
ES (2) ES2529724T3 (de)
IL (2) IL189665A (de)
JO (1) JO2655B1 (de)
MA (1) MA29787B1 (de)
MX (1) MX2008003170A (de)
NO (1) NO20081727L (de)
NZ (2) NZ588372A (de)
PL (2) PL1926483T3 (de)
PT (2) PT2295049E (de)
RU (2) RU2424795C2 (de)
SG (1) SG165364A1 (de)
SI (2) SI2295049T1 (de)
TN (1) TNSN08103A1 (de)
TW (2) TWI372620B (de)
WO (1) WO2007028821A2 (de)
ZA (1) ZA200801694B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
AU2005292984B2 (en) 2004-10-12 2011-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrate thereof and intermediate for the same
RU2421214C2 (ru) * 2005-10-07 2011-06-20 Киорин Фармасьютикал Ко., Лтд. Терапевтическое средство для лечения гепатита и способ лечения гепатита
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
US8232319B2 (en) * 2006-08-08 2012-07-31 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and S1P receptor modulator having same as an active ingredient
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
JP5198293B2 (ja) * 2007-02-13 2013-05-15 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
EP2305305A4 (de) * 2008-05-20 2013-02-13 Kyorin Seiyaku Kk Mittel zur einleitung/erhaltung der remission
CA2734585A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
NZ603999A (en) * 2010-05-06 2014-06-27 Novartis Ag Treatment of autoimmune diseases
AU2011249789B2 (en) * 2010-05-06 2015-03-19 Novartis Ag Dosage regimen of diaryl sulfide derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
ATE463478T1 (de) * 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003264430B2 (en) * 2002-09-19 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
MXPA05003254A (es) * 2002-09-24 2005-06-08 Novartis Ag Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
KR100995486B1 (ko) * 2002-09-28 2010-11-22 맥네일-피피씨, 인코포레이티드 개구가 있는 쉘을 포함하는 속방성 투여형
DK1602660T3 (da) 2003-02-18 2011-05-23 Kyorin Seiyaku Kk Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
DE202004021680U1 (de) * 2003-04-08 2010-04-22 Novartis Ag Feste pharmazeutische Zusammensetzung
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
MXPA06002349A (es) * 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
ATE502630T1 (de) * 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MX2008003170A (es) 2008-03-18
JP6077265B2 (ja) 2017-02-08
KR20140117704A (ko) 2014-10-07
IL189665A (en) 2014-07-31
CY1111285T1 (el) 2015-08-05
SI2295049T1 (sl) 2015-03-31
KR20080046231A (ko) 2008-05-26
HK1149906A1 (en) 2011-10-21
DK2295049T3 (en) 2015-02-23
KR101476591B1 (ko) 2014-12-24
US20080200438A1 (en) 2008-08-21
JP2013010802A (ja) 2013-01-17
CA2620554A1 (en) 2007-03-15
EP1926483A2 (de) 2008-06-04
PL1926483T3 (pl) 2011-05-31
RU2424795C2 (ru) 2011-07-27
JO2655B1 (en) 2012-06-17
TW200803829A (en) 2008-01-16
AU2006289100A1 (en) 2007-03-15
IL233328A0 (en) 2014-08-31
CN101257899A (zh) 2008-09-03
PT1926483E (pt) 2011-03-03
AU2010224355B2 (en) 2012-03-29
EP1926483B1 (de) 2010-12-01
KR20140019033A (ko) 2014-02-13
IL189665A0 (en) 2008-06-05
PT2295049E (pt) 2015-03-02
TWI376223B (en) 2012-11-11
CA2620554C (en) 2013-12-17
TNSN08103A1 (en) 2009-07-14
KR101476451B1 (ko) 2014-12-24
RU2011111117A (ru) 2012-09-27
RU2493840C2 (ru) 2013-09-27
EP2295049A1 (de) 2011-03-16
BRPI0615906A2 (pt) 2011-05-31
CA2820510A1 (en) 2007-03-15
SI1926483T1 (sl) 2011-04-29
NO20081727L (no) 2008-06-06
SG165364A1 (en) 2010-10-28
CN101257899B (zh) 2012-10-03
ES2357426T3 (es) 2011-04-26
NZ588372A (en) 2012-03-30
TWI372620B (en) 2012-09-21
NZ566137A (en) 2011-05-27
JP2017019854A (ja) 2017-01-26
DK1926483T3 (da) 2011-03-14
JP2009507810A (ja) 2009-02-26
EP2295049B1 (de) 2014-11-26
RU2008113187A (ru) 2009-10-20
JP5244598B2 (ja) 2013-07-24
AU2010224355A1 (en) 2010-10-14
AU2006289100B2 (en) 2010-07-22
WO2007028821A3 (en) 2007-05-03
ZA200801694B (en) 2009-09-30
WO2007028821A2 (en) 2007-03-15
MA29787B1 (fr) 2008-09-01
TW201034659A (en) 2010-10-01
JP2015025002A (ja) 2015-02-05
DE602006018629D1 (de) 2011-01-13
ES2529724T3 (es) 2015-02-25
PL2295049T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
IL233328A0 (en) Treatment of autoimmune diseases
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
TW200509892A (en) Novel aminobenzophenone compounds
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
DK1567488T3 (da) Hydroxyethylaminderivater til behandling af Alzheimers sygdom
EA201070247A1 (ru) Ингибиторы протеасом
EA200802054A1 (ru) Ингибиторы фермента
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EA201170344A1 (ru) Азаиндольные ингибиторы iap
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
EA200800342A1 (ru) ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
BRPI0512732A (pt) formulações tópicas para tratamento de doenças alérgicas
EA200701815A1 (ru) 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний
CY1116051T1 (el) Θεραπεια αυτοανοσων ασθενειων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1926483

Country of ref document: EP